Compare BGC & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGC | KRYS |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 6.3B |
| IPO Year | 1999 | 2017 |
| Metric | BGC | KRYS |
|---|---|---|
| Price | $9.11 | $253.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $14.50 | ★ $214.22 |
| AVG Volume (30 Days) | ★ 2.7M | 322.3K |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | 36.46 | ★ 275.72 |
| EPS | 0.33 | ★ 6.66 |
| Revenue | ★ $2,640,884,000.00 | $373,164,000.00 |
| Revenue This Year | $36.34 | $36.14 |
| Revenue Next Year | $11.45 | $41.80 |
| P/E Ratio | ★ $27.20 | $37.47 |
| Revenue Growth | 24.59 | ★ 54.51 |
| 52 Week Low | $7.24 | $122.80 |
| 52 Week High | $10.96 | $249.78 |
| Indicator | BGC | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 58.34 | 75.77 |
| Support Level | $8.89 | $231.69 |
| Resistance Level | $9.05 | $248.60 |
| Average True Range (ATR) | 0.18 | 8.22 |
| MACD | 0.04 | 0.44 |
| Stochastic Oscillator | 89.29 | 97.16 |
BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.